基于国家专利的中药复方治疗心律失常证候配伍规律研究(1)
摘要：目的 分析國家专利数据库中治疗心律失常中药复方用药规律，为新药研发提供参考。方法 计算机检索国家专利数据库2003年4月-2018年1月收录的治疗心律失常中药复方专利数据。采用中医传承辅助平台(V2.5)集成的药物频次、关联规则、复杂网络、熵聚类等方法，分析中药复方专利的主治证候及配伍规律。结果 纳入治疗心律失常的中药复方专利149项，包含药物614味。最常见的主治证候为心血瘀阻证(65次、43.62%);高频药物有麦冬(43次、28.86%)、丹参(42次、28.19%)、炙甘草(37次、24.83%)、党参(34次、22.82%)、黄芪(34次、22.82%)等;常见药对有“麦冬-丹参”“炙甘草-党参”“麦冬-黄芪”等;常见角药有“炙甘草-麦冬-生地黄”“麦冬-丹参-人参”“麦冬-桂枝-五味子”等;重要关联规则有“炙甘草、生地黄→麦冬”“赤芍、人参→丹参”“柏子仁，黄芪→五味子”等;熵层次聚类得到的新处方有“党参、酸枣仁、人参、炙甘草”“琥珀、甘松、黄精、赤芍、山茱萸”等。结论 研发治疗心律失常的高效新药时，可考虑以心血瘀阻证为主治证候，以麦冬、丹参、炙甘草等为处方核心药物配伍加减。
关键词：心律失常;中药复方;专利;证候;配伍规律
DOI：10.3969/j.issn.1005-5304.2018.10.023
中图分类号：R2-05;R259.417 文献标识码：A 文章编号：1005-5304(2018)10-0106-05
Study onCompatibilityRulesof TCM CompoundsforTreatment ofArrhythmiaSyndromesBased onNationalPatent
YIN Chun-yuan1，2， LIU Jian-xun1
1. Institute of Basic Medical Science of Xiyuan Hospital， China Academy of Chinese Medical Sciences， Beijing Key Laboratory of Pharmacology of Chinese Materia Medica， Beijing 100091， China; 2. Beijing University of Chinese Medicine， Beijing 100029， China
Abstract： Objective To analyze medication rules of TCM compounds forthe treatment of arrhythmia in the national patent database; To provide references for research and development of new medicine. MethodsComputers were used to search the patent data about TCM compounds for the treatment of arrhythmia in National Patent Database from April 2003 to January 2018. Medicine frequency， association rules， complex networks， entropy clustering of Chinese auxiliary system (V2.5) were used to analyze treatment syndromes and compatibility rules. Results Totally 149 TCM compound patents for the treatment of arrhythmia were involved， including 614 kinds of Chinese materia medica. The most common treatment syndrome was heart-blood stasis syndrome (65 times， 43.62%). The medicines with high frequency were Ophiopogonis Radix (43 times， 28.86%)， Salviae Miltiorrhizae Radix et Rhizoma (42 times， 28.19%)， Glycyrrhizae Radix et Rhizoma Praeparata cum Melle (37 times， 24.83%)， Codonopsis Radix (34 times， 22.82%)， Astragali Radix (34 times， 22.82%) and so on. The common medicinal pairs were “Ophiopogonis Radix - Salviae Miltiorrhizae Radix”， “Glycyrrhizae Radix et Rhizoma Praeparata cum Melle - Codonopsis Radix”， and “Ophiopogonis Radix - Astragali Radix”. The common triple medicinal combinations were “Glycyrrhizae Radix et Rhizoma Praeparata cum Melle - Ophiopogonis Radix - raw Rehmanniae Radix”， “Ophiopogonis Radix - Salviae Miltiorrhizae Radix et Rhizoma - Ginseng Radix et Rhizoma”， and “Ophiopogonis Radix-Cinnamomi Ramulus-Schisandrae Chinensis Fructus”. The important association rules were “GlycyrrhizaeRadix et Rhizoma Praeparata cum Melle， raw Rehmanniae Radix → Ophiopogonis Radix”， “Paeoniae Radix Rubra， Ginseng Radix et Rhizoma → Salviae Miltiorrhizae Radix”， and “Platycladi Semen， Astragali Radix → Schisandrae Chinensis Fructus”. New prescriptions obtained by entropy clustering were “Codonopsis Radix， Ziziphi Spinosae Semen， Ginseng Radix et Rhizoma， and Glycyrrhizae Radix et Rhizoma Praeparata cum Melle”， “Amber， Nardostachyos Radix et Rhizoma， Polygonati Rhizoma， Paeoni Aeradix Rubra， and Corni Fructus”. Conclusion When developing high-efficiency new medicines for the treatment of arrhythmia， heart-blood stasis syndrome is considered as the treatment syndrome. The core medicines in prescriptions should be modified compatibility of Ophiopogonis Radix， Salviae Miltiorrhizae Radix et Rhizoma and Glycyrrhizae Radix et Rhizoma Praeparata cum Melle., 百拇医药(尹春园 刘建勋)
关键词：心律失常;中药复方;专利;证候;配伍规律
DOI：10.3969/j.issn.1005-5304.2018.10.023
中图分类号：R2-05;R259.417 文献标识码：A 文章编号：1005-5304(2018)10-0106-05
Study onCompatibilityRulesof TCM CompoundsforTreatment ofArrhythmiaSyndromesBased onNationalPatent
YIN Chun-yuan1，2， LIU Jian-xun1
1. Institute of Basic Medical Science of Xiyuan Hospital， China Academy of Chinese Medical Sciences， Beijing Key Laboratory of Pharmacology of Chinese Materia Medica， Beijing 100091， China; 2. Beijing University of Chinese Medicine， Beijing 100029， China
Abstract： Objective To analyze medication rules of TCM compounds forthe treatment of arrhythmia in the national patent database; To provide references for research and development of new medicine. MethodsComputers were used to search the patent data about TCM compounds for the treatment of arrhythmia in National Patent Database from April 2003 to January 2018. Medicine frequency， association rules， complex networks， entropy clustering of Chinese auxiliary system (V2.5) were used to analyze treatment syndromes and compatibility rules. Results Totally 149 TCM compound patents for the treatment of arrhythmia were involved， including 614 kinds of Chinese materia medica. The most common treatment syndrome was heart-blood stasis syndrome (65 times， 43.62%). The medicines with high frequency were Ophiopogonis Radix (43 times， 28.86%)， Salviae Miltiorrhizae Radix et Rhizoma (42 times， 28.19%)， Glycyrrhizae Radix et Rhizoma Praeparata cum Melle (37 times， 24.83%)， Codonopsis Radix (34 times， 22.82%)， Astragali Radix (34 times， 22.82%) and so on. The common medicinal pairs were “Ophiopogonis Radix - Salviae Miltiorrhizae Radix”， “Glycyrrhizae Radix et Rhizoma Praeparata cum Melle - Codonopsis Radix”， and “Ophiopogonis Radix - Astragali Radix”. The common triple medicinal combinations were “Glycyrrhizae Radix et Rhizoma Praeparata cum Melle - Ophiopogonis Radix - raw Rehmanniae Radix”， “Ophiopogonis Radix - Salviae Miltiorrhizae Radix et Rhizoma - Ginseng Radix et Rhizoma”， and “Ophiopogonis Radix-Cinnamomi Ramulus-Schisandrae Chinensis Fructus”. The important association rules were “GlycyrrhizaeRadix et Rhizoma Praeparata cum Melle， raw Rehmanniae Radix → Ophiopogonis Radix”， “Paeoniae Radix Rubra， Ginseng Radix et Rhizoma → Salviae Miltiorrhizae Radix”， and “Platycladi Semen， Astragali Radix → Schisandrae Chinensis Fructus”. New prescriptions obtained by entropy clustering were “Codonopsis Radix， Ziziphi Spinosae Semen， Ginseng Radix et Rhizoma， and Glycyrrhizae Radix et Rhizoma Praeparata cum Melle”， “Amber， Nardostachyos Radix et Rhizoma， Polygonati Rhizoma， Paeoni Aeradix Rubra， and Corni Fructus”. Conclusion When developing high-efficiency new medicines for the treatment of arrhythmia， heart-blood stasis syndrome is considered as the treatment syndrome. The core medicines in prescriptions should be modified compatibility of Ophiopogonis Radix， Salviae Miltiorrhizae Radix et Rhizoma and Glycyrrhizae Radix et Rhizoma Praeparata cum Melle., 百拇医药(尹春园 刘建勋)